TrialCNS drugs2013

Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.

Ralf W Dittmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.